Published in Ann Rheum Dis on November 01, 1973
Association of inflammation with raised serum IgA in ankylosing spondylitis. Ann Rheum Dis (1980) 2.09
Non-secretion of ABO blood group antigens as a host susceptibility factor in the spondyloarthropathies. Br Med J (Clin Res Ed) (1987) 1.91
Interactions of the innate and adaptive arms of the immune system in the pathogenesis of spondyloarthritis. Clin Exp Rheumatol (2011) 1.45
A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother (2013) 1.24
Acute-phase proteins and serum immunoglobulins in ankylosing spondylitis. Ann Rheum Dis (1983) 1.19
Immunological reactivity in ankylosing spondylitis. Circulating immunoblasts, autoantibodies, and immunoglobulins. Ann Rheum Dis (1976) 1.12
A comparison of serum biochemistry in ankylosing spondylitis, seronegative and seropositive rheumatoid arthritis. Ann Rheum Dis (1981) 1.06
The link between ankylosing spondylitis, Crohn's disease, Klebsiella, and starch consumption. Clin Dev Immunol (2013) 0.94
Correlation of immunoglobulin and C reactive protein levels in ankylosing spondylitis and rheumatoid arthritis. Ann Rheum Dis (1987) 0.93
The use of a low starch diet in the treatment of patients suffering from ankylosing spondylitis. Clin Rheumatol (1996) 0.92
IgM, IgG, and IgA synthesis in vitro in persons suffering from yersinia arthritis and in patients with ankylosing spondylitis. Ann Rheum Dis (1984) 0.86
Increased levels of serum IgA as IgA1 monomers in ankylosing spondylitis. Ann Rheum Dis (1992) 0.84
Ankylosing spondylitis and monoclonal gammopathies. Ann Rheum Dis (1992) 0.84
Red blood cell distribution width: a potential maker estimating disease activity of ankylosing spondylitis. Int J Clin Exp Med (2014) 0.83
Differences in HLA-B27 positive and negative patients with ankylosing spondylitis: study of clinical disease activity and concentrations of serum IgA, C reactive protein, and haptoglobin. Ann Rheum Dis (1991) 0.82
The role of the gut and microbes in the pathogenesis of spondyloarthritis. Best Pract Res Clin Rheumatol (2014) 0.82
IgA and IgA-specific receptors in human disease: structural and functional insights into pathogenesis and therapeutic potential. Springer Semin Immunopathol (2006) 0.81
IgA-alpha 1 antitrypsin complexes in ankylosing spondylitis. Ann Rheum Dis (1989) 0.79
Polyclonal B cell activation in ankylosing spondylitis. Ann Rheum Dis (1990) 0.78
IgG and IgA immune response against klebsiella in HLA-B27-associated anterior uveitis. Br J Ophthalmol (1986) 0.76
Risk factors for urolithiasis in patients with ankylosing spondylitis: a prospective case-control study. Urolithiasis (2016) 0.75
Subpopulations of T lymphocytes in patients with ankylosing spondylitis. Ann Rheum Dis (1980) 0.75
Immunoregulatory T cells in the peripheral blood of patients with Bechterew's syndrome. Ann Rheum Dis (1982) 0.75
Role of protein phosphatase magnesium-dependent 1A and anti-protein phosphatase magnesium-dependent 1A autoantibodies in ankylosing spondylitis. Arthritis Rheumatol (2014) 0.75
Higher Levels of Secretory IgA Are Associated with Low Disease Activity Index in Patients with Reactive Arthritis and Undifferentiated Spondyloarthritis. Front Immunol (2017) 0.75
Urolithiasis as an extraarticular manifestation of ankylosing spondylitis. Rheumatol Int (2017) 0.75
Infliximab treatment in two patients with psoriatic arthritis and secondary IgA nephropathy. Clin Rheumatol (2006) 0.75
Immuno-electrophoretic analysis of proteins in serum and synovial fluid in rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis (1961) 1.39
[ON THE POSSIBLE VIRAL ORIGIN OF THE OCULO-URETHRO-SYNOVIAL SYNDROME]. Presse Med (1965) 1.07
Differentiation of inflammation and ossification in spondylarthritis ankylopoietica. Acta Rheumatol Scand (1971) 1.06
Strontium 87m scanning of the sacroiliac joints in ankylosing spondylitis. Ann Rheum Dis (1972) 1.03
Complement-fixing antibodies to bedsonia organisms in Reiter's syndrome and ankylosing spondylitis. Ann Rheum Dis (1968) 1.03
[The immunoglobulins in ankylosing spondylitis]. Verh Dtsch Ges Rheumatol (1969) 0.98
A double-linear immunodiffusion method for the quantitation of proteins. Clin Chim Acta (1970) 0.97
Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies. Arthritis Rheum (2001) 2.96
Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis (2004) 2.18
Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis (2004) 2.15
A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study. Rheumatology (Oxford) (2005) 2.05
The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol (1995) 1.99
Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis (2000) 1.79
Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis (2002) 1.76
Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum (2001) 1.70
Ileocolonoscopic findings in seronegative spondylarthropathies. Br J Rheumatol (1988) 1.55
The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol (1995) 1.51
Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity. Ann Rheum Dis (2000) 1.47
Serum levels of IgG, IgM, and IgA in rheumatoid arthritis. Ann Rheum Dis (1968) 1.45
Gut inflammation in the spondyloarthropathies: clinical, radiologic, biologic and genetic features in relation to the type of histology. A prospective study. J Rheumatol (1991) 1.45
The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects. J Rheumatol (1995) 1.44
Etiological factors and underlying conditions in patients with leucocytoclastic vasculitis. Clin Exp Rheumatol (1997) 1.42
Human cartilage gp-39+,CD16+ monocytes in peripheral blood and synovium: correlation with joint destruction in rheumatoid arthritis. Arthritis Rheum (2000) 1.39
Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol (2000) 1.37
Needle arthroscopy of the knee with synovial biopsy sampling: technical experience in 150 patients. Clin Rheumatol (1999) 1.36
Characterisation of human knee meniscus cell phenotype. Osteoarthritis Cartilage (2005) 1.34
Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus. Ann Rheum Dis (2004) 1.32
Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis (2005) 1.31
Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis (2003) 1.31
Anti-perinuclear factor compared with the so called "antikeratin" antibodies and antibodies to human epidermis filaggrin, in the diagnosis of arthritides. Ann Rheum Dis (1999) 1.30
Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology (Oxford) (1999) 1.28
HLA-B27 related arthritis and bowel inflammation. Part 2. Ileocolonoscopy and bowel histology in patients with HLA-B27 related arthritis. J Rheumatol (1985) 1.23
Numerical scoring systems for the anatomic evolution of osteoarthritis of the finger joints. Arthritis Rheum (1996) 1.21
Evaluation of T cell subsets with monoclonal antibodies in patients with rheumatoid arthritis. J Rheumatol (1982) 1.19
The antiperinuclear factor. Clin Exp Rheumatol (1991) 1.18
Subclinical involvement of the gut in undifferentiated spondylarthropathies. Clin Exp Rheumatol (1990) 1.16
Onset of symptoms of rheumatoid arthritis in relation to age, sex and menopausal transition. J Rheumatol (1990) 1.16
A prospective study of patients with spondyloarthropathy with special reference to HLA-B27 and to gut histology. J Rheumatol (1993) 1.15
Letter: Levamisole in rheumatoid arthritis. Lancet (1976) 1.15
The diagnostic significance of the antiperinuclear factor for rheumatoid arthritis. J Rheumatol (1988) 1.15
Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha. Ann Rheum Dis (2001) 1.13
Levamisole-induced adverse reactions in HLA B27-positive rheumatoid arthritis. Lancet (1978) 1.13
Diagnostic associations in a large and consecutively identified population positive for anti-SSA and/or anti-SSB: the range of associated diseases differs according to the detailed serotype. Ann Rheum Dis (2002) 1.11
Anti-citrullinated protein/peptide antibodies (ACPA) in rheumatoid arthritis: specificity and relation with rheumatoid factor. Autoimmun Rev (2005) 1.10
Involvement of the zygapophyseal joint in ankylosing spondylitis: relation to the bridging syndesmophyte. J Rheumatol (1999) 1.10
Gut inflammation in children with late onset pauciarticular juvenile chronic arthritis and evolution to adult spondyloarthropathy--a prospective study. J Rheumatol (1993) 1.09
Determination of T lymphocyte subpopulations by monoclonal antibodies in rheumatoid arthritis. Influence of immunomodulating agents. Int J Immunopharmacol (1981) 1.06
CARD15 gene polymorphisms in patients with spondyloarthropathies identify a specific phenotype previously related to Crohn's disease. Ann Rheum Dis (2004) 1.06
Bowel inflammation and the spondyloarthropathies. Rheum Dis Clin North Am (1998) 1.06
Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy. Ann Rheum Dis (2004) 1.06
Detection and identification of antinuclear antibodies (ANA) in a large and consecutive cohort of serum samples referred for ANA testing. Ann Rheum Dis (2001) 1.05
The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. Lupus (2005) 1.05
Gout and its relation to lipid metabolism. I. Serum uric acid, lipid, and lipoprotein levels in gout. Ann Rheum Dis (1973) 1.03
Strontium 87m scanning of the sacroiliac joints in ankylosing spondylitis. Ann Rheum Dis (1972) 1.03
Clinical and radiographic features of Reiter's syndrome and inflammatory bowel disease related to arthritis. Curr Opin Rheumatol (1990) 1.03
Detection and identification of antinuclear autoantibodies in the serum of normal blood donors. Clin Exp Rheumatol (1993) 1.01
Course of gut inflammation in spondylarthropathies and therapeutic consequences. Baillieres Clin Rheumatol (1996) 0.98
Chemical agents and enzymes used for the extraction of gut lymphocytes influence flow cytometric detection of T cell surface markers. J Immunol Methods (2000) 0.97
Presence of rheumatoid factor and antibodies to citrullinated peptides in systemic lupus erythematosus. Ann Rheum Dis (2005) 0.97
A double-linear immunodiffusion method for the quantitation of proteins. Clin Chim Acta (1970) 0.97
HLA-B27 related arthritis and bowel inflammation. Part 1. Sulfasalazine (salazopyrin) in HLA-B27 related reactive arthritis. J Rheumatol (1985) 0.96
Intestinal mucosal permeability in inflammatory rheumatic diseases. I. Role of antiinflammatory drugs. J Rheumatol (1991) 0.96
Homeostasis of the extracellular matrix of normal and osteoarthritic human articular cartilage chondrocytes in vitro. Osteoarthritis Cartilage (2003) 0.96
Involvement of neurotrophins and their receptors in spondyloarthritis synovitis: relation to inflammation and response to treatment. Ann Rheum Dis (2005) 0.96
The efficacy and toxicity of a constant low dose of methotrexate as a treatment for intractable rheumatoid arthritis: an open prospective study. J Rheumatol (1991) 0.96
Anti-Ro52 reactivity is an independent and additional serum marker in connective tissue disease. Ann Rheum Dis (2002) 0.96
Numerical scoring systems for the progression of osteoarthritis of the finger joints. Rev Rhum Engl Ed (1995) 0.95
Anti-saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy. Ann Rheum Dis (2003) 0.95
Colon mucosa of patients both with spondyloarthritis and Crohn's disease is enriched with macrophages expressing the scavenger receptor CD163. Ann Rheum Dis (2004) 0.95
Gut inflammation in psoriatic arthritis: a prospective ileocolonoscopic study. J Rheumatol (1995) 0.94
The gut in the spondyloarthropathies. J Rheumatol (1990) 0.94
HLA antigens in seronegative spondylarthropathies. Reactive arthritis and arthritis in ankylosing spondylitis: relation to gut inflammation. J Rheumatol (1987) 0.94
Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs. Clin Rheumatol (2002) 0.94
Intestinal mucosal permeability in inflammatory rheumatic diseases. II. Role of disease. J Rheumatol (1991) 0.94
Flow cytometric analysis of gut mucosal lymphocytes supports an impaired Th1 cytokine profile in spondyloarthropathy. Ann Rheum Dis (2001) 0.94
Repeat ileocolonoscopy in reactive arthritis. J Rheumatol (1987) 0.94
Comparison of serum salicylate levels and gastro-intestinal blood loss between salsalate (Disalcid)and other forms of salicylates. Scand J Rheumatol (1981) 0.94
Experience and recommendations for treatment schedule of levamisole in rheumatoid arthritis. J Rheumatol Suppl (1978) 0.93
The proportion of Th1 cells, which prevail in gut mucosa, is decreased in inflammatory bowel syndrome. Clin Exp Immunol (2001) 0.93
Tumour necrosis factor alpha independent disease mechanisms in rheumatoid arthritis: a histopathological study on the effect of infliximab on rheumatoid nodules. Ann Rheum Dis (2004) 0.93
Technical validation of cDNA based microarray as screening technique to identify candidate genes in synovial tissue biopsy specimens from patients with spondyloarthropathy. Ann Rheum Dis (2004) 0.92
Melanoma inhibitory activity, a biomarker related to chondrocyte anabolism, is reversibly suppressed by proinflammatory cytokines in rheumatoid arthritis. Ann Rheum Dis (2008) 0.92
Focal up-regulation of E-cadherin-catenin complex in inflamed bowel mucosa but reduced expression in ulcer-associated cell lineage. Am J Clin Pathol (2000) 0.92
Enrichment of T cells carrying beta7 integrins in inflamed synovial tissue from patients with early spondyloarthropathy, compared to rheumatoid arthritis. J Rheumatol (1998) 0.91
B27 and agranulocytosis in rheumatoid arthritis patients treated with levamisole. Acta Rhumatol (2001) 0.90
Distinctive activated cellular subsets in colon from patients with Crohn's disease and ulcerative colitis. Scand J Gastroenterol (1998) 0.90
Sulphasalazine (Salazopyrin) in the treatment of enterogenic reactive synovitis and ankylosing spondylitis with peripheral arthritis. Clin Rheumatol (1986) 0.90
Candida glabrata arthritis: case report and review of the literature of Candida arthritis. Clin Rheumatol (1999) 0.90
Chondroitin sulfate: S/DMOAD (structure/disease modifying anti-osteoarthritis drug) in the treatment of finger joint OA. Osteoarthritis Cartilage (1998) 0.89
Churg-Strauss syndrome presenting as polymyositis. Clin Exp Rheumatol (1995) 0.89
Evaluation of T cell subsets with monoclonal antibodies in synovial fluid in rheumatoid arthritis. J Rheumatol (1983) 0.89
T lymphocytes in blood and synovial fluid in rheumatoid arthritis. Lancet (1982) 0.89
Opportunities for immune modulation in the spondyloarthropathies with special reference to gut inflammation. Inflamm Res (2000) 0.88
Increase in lymphoid follicles and leukocyte adhesion molecules emphasizes a role for the gut in spondyloarthropathy pathogenesis. J Pathol (2002) 0.88
Subclinical gut inflammation in spondyloarthropathy patients is associated with upregulation of the E-cadherin/catenin complex. Ann Rheum Dis (2000) 0.88
Influence of low dose corticosteroid administration on the lymphocytes subpopulations. J Rheumatol (1982) 0.88
Control of extracellular matrix homeostasis of normal cartilage by a TGFbeta autocrine pathway. Validation of flow cytometry as a tool to study chondrocyte metabolism in vitro. Osteoarthritis Cartilage (2002) 0.88
Effect of age on prevalence of anticitrullinated protein/peptide antibodies in polyarticular juvenile idiopathic arthritis. Rheumatology (Oxford) (2005) 0.88
Synovial inflammation does not change in the absence of effective treatment: implications for the use of synovial histopathology as biomarker in early phase clinical trials in rheumatoid arthritis. Ann Rheum Dis (2006) 0.87
Interpretation of ileal biopsies: morphological features in normal and diseased mucosa. Histopathology (2001) 0.87
A study of the hematological side effects of levamisole in rheumatoid arthritis with recommendations. J Rheumatol Suppl (1978) 0.87
Peripheral blood T lymphocyte subpopulations determined by monoclonal antibodies in active rheumatoid arthritis. J Rheumatol (1986) 0.87
Avascular necrosis and its relation to lipid and purine metabolism. J Rheumatol (1975) 0.87
Altered expression of alpha E beta 7 integrin on intra-epithelial and lamina propria lymphocytes in patients with Crohn's disease. Acta Gastroenterol Belg (1998) 0.86
Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during tumour necrosis factor alpha blockade. Ann Rheum Dis (2008) 0.85
A comparative phenotypical analysis of rheumatoid nodules and rheumatoid synovium with special reference to adhesion molecules and activation markers. Ann Rheum Dis (1998) 0.85
Familial aggregation in seronegative spondyloarthritis of enterogenic origin. A family study. J Rheumatol (1986) 0.85